According to GRI Bio, the data shows that GRI-0621 directly impacts the core biology of IPF, with differentially expressed ...
Stocktwits on MSN
GRI Bio reports positive study results for chronic lung disease, but stock slumps 20% — what happened?
The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung ...
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, ...
Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock. ImmunityBio ( ...
Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results